Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: June 18, 2021
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: April 30, 2021
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Journal: British journal of cancer
Published: February 08, 2018
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 22, 2016
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 19, 2016
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Journal: NPJ systems biology and applications
Published: July 05, 2016
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: November 30, 2015
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).
Journal: Molecular cancer therapeutics
Published: April 17, 2015
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Journal: Molecular cancer therapeutics
Published: February 25, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026